Fard MK, et al. - In this triple-blind, randomized controlled clinical trial, researchers determined the impact of alendronate on plasma glucose and insulin indices of 60 postmenopausal women (aged 45–60 years) with prediabetes and osteopenia. All participants in the study were vitamin D sufficient and were randomly registered in the intervention (70 mg/week alendronate for 12 weeks) and control (placebo tablet per week for 12 weeks) groups. Among osteopenic prediabetic postmenopausal women, administration of 70 mg/week alendronate improved fasting plasma glucose, hemoglobin A1c (HbA1c), and insulin indices.